Sector Expert: Dan Swisher, Jr.
Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals, Inc., joined Sunesis as the chief business officer in 2001. In 2003, he became chief financial officer and, in 2005, he was promoted to his current position. Prior to joining Sunesis, Mr. Swisher served in various management roles, including senior vice president of sales and marketing for ALZA Corp. from 1992 to 2001. He also serves as chairman of the board of Cerus Corp., a biopharmaceutical company. Mr. Swisher holds a bachelor's degree from Yale University, and a master's degree in business administration from the Stanford Graduate School of Business.
How Sunesis Pharmaceuticals Can Inhibit Cancer While Enhancing Investments: CEO Daniel Swisher (4/2/15)
Cancers are among today's most significant unmet medical needs. Take, for example, acute myelogenous leukemia: No new therapeutics have hit the marketplace in more than forty years. In this interview with The Life Sciences Report, Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals Inc., describes how his company is making clinical progress toward developing a new treatment for this devastating disease, and how the broad Sunesis kinase inhibitor portfolio provides additional firepower against other cancers. With a number of share-moving catalysts on the horizon, Sunesis expects to hit the mark both for patients and investors.